Features of Clinical Manifestations in Patients with Microvascular Angina
Downloads
Research into the various mechanisms underlying coronary artery disease (CAD) has revealed a condition in which chest pain and signs of myocardial ischemia develop despite intact coronary arteries, a condition first described by H. Kemp in 1973 as "cardiac syndrome X. " In 1988, S. Epsten and R. O. Cannon introduced the term "microvascular angina," demonstrating that the disease is caused by changes in the heart's microvessels. This article presents various perspectives on microvascular angina (MVA), ranging from the onset of the disease, invasive and noninvasive diagnostic methods, to treatment and prevention.
1. Arthur HM, Campbell P., Harvey PJ Women, cardiac syndrome X and microvascular heart disease // Can. J. Cardiol. 2012. N 2. pp. 42-49. DOI: 10.1016/j.cjca.2011.09.006.
2. Badimon L., Bugiardini R., Cenko E., Position paper of the European Society of Cardiology working group of coronary pathophysiology and microcirculation: obesity and heart disease // Eur. Heart J. 2017. N 38(25). pp. 1951-1958. DOI: 10.1093/eurhertj/ehx181.
3. Beltrame JF, Crea F., Kaski JC International standardization of diagnostic criteria for vasospastic angina // Eur. Heart J. 2017. N 38. pp. 2565-2568. DOI: 10.1093/eurheartj/ehv351.
4. Brainin P., Frestad D., Prescott E. The prognostic value of coronary endothelial and microvascular dysfunction in subjects with normal or non-obstructive coronary artery disease: a systematic review and meta-analysis // Int. J. Cardiol. 2018. N 254. pp. 1-9.
5. Bugiardini R., Manfrini O., Pizzi C. Endothelial function predicts future development of coronary artery disease: a study of women with chest pain and normal coronary angiograms // Circulation. 2004. N 109. pp. 2518-2523.
6. Camici PG, d'Amati G., Rimoldi O. Coronary microvascular dysfunction: mechanisms and functional assessment // Nat. Rev. Cardiol. 2015. N 12. pp. 48-62. DOI: 10.1038/nrcardio.2014.160.
7. Cattaneo M., Porretta AP, Gallino A. Ranolazine: Drug overview and possible role in primary microvascular angina management // International journal of cardiology. 2014. vol. 181. pp. 376-381.
8. Celeng C., Leiner T., Maurovich-Horvat P., Anatomical and functional computed tomography for diagnosing hemodynamically significant coronary artery disease: a meta-analysis // JACC Cardiovasc. Imaging. 2019. N 12(7.2). pp. 1316-1325. DOI: 10.1016/j.jcmg.2018.07.022.
9. Chen C., Wei J., Al Badri A., Coronary Microvascular Dysfunction Epidemiology, Pathogenesis, Prognosis, Diagnosis, Risk Factors and Therapy // Circ. J. 2016. N 81(1). pp. 3-11. DOI: 10.1253/circj.CJ-16-1002.
10. Cotrim C., Almeida AG, Carrageta M. Cardiac syndrome X, intraventricular gradients and beta-blockers // Revista portuguesa de cardiologia. 2010. vol. 29, N 2. pp. 193-203.
11. Crea F., Camici PG, Bairey Merz CN Coronary microvascular dysfunction: an update // European Heart Journal. 2014. N 35(17). pp. 1101-1111.
12. Crea F., Lanza GA, Camici PG Coronary Microvascular Dysfunction/ Milan: Springer. 2014. 212 P.
13. Crea F., Montone RA, Rinaldi R. Pathophysiology of Coronary Microvascular Dysfunction // Circ. J. 2022. N 86(9). pp. 1319-1328. DOI: 10.1253/circj.CJ-21-0848.
14. Eshtehardi P., McDaniel MC, Dhawan SS Effect of intensive atorvastatin therapy on coronary atherosclerosis progression, composition, arterial remodeling and microvascular function // J. Invasive Cardiol. 2012. N 24(10). pp. 522-9.
15. Godo S., Suda A., Takahashi J. Coronary Microvascular Dysfunction// Arterioscler. Thromb. Vasc. Biol. 2021. N 41(5). pp. 1625-37. DOI: 10.1161/ ATVBAHA.121.316025.
16. Lanza GA, Gaspardone A., Pasceri V. Effects of bamiphylline ob exercise testing in patients with syndrome X// G. Ital. Cardiol. 1997. vol. 27, N 1. P. 50-54.
17. Lanza GA, Stazi F. Colonna G. Circadian variation of ischemic threshold in syndrome X// Am. G. Cardiol. 1995. vol. 75, N 10. P. 683-686.
18. Liu A., Wijesurendra RS, Liu JM Diagnosis of microvascular angina using cardiac magnetic resonance // J. Am. Coll. Cardiol. 2018. N 71. pp. 969-979. DOI: 10.1016/j.jacc.2017.12.046.
19. Merz CNB, Handberg EM, Shufelt CL, Mehta PK, Minissian MB A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve // Eur. Heart. J. 2015. N 2. pp. ehv647-648.
20. Merz CNB, Pepine CJ, Shimokawa H., Berry C. Treatment of coronary microvascular dysfunction // Cardiovasc. Res. 2020. N 116(4). pp. 856-870. DOI: 10.1093/cvr/cvaa006.
21. Rayner-Hartley E., Parvand M., Humphries KH Ranolazine for Symptomatic Management of Microvascular Angina // Am J Ther. 2020. N 27(2). pp. e151-e158. DOI: 10.1097/MJT.0000000000000779.
22. Tondi P., Santoliquido A., Di Giorgio A. Endothelial dysfunction as assessed by flow-mediated dilation in patients with cardiac syndrome X: role of inflammation// European review for medical and pharmacological sciences. 2011. vol. 15, N 9. pp. 1074-1077.
